Coherence properties of infrared thermal emission from heated metallic nanowires

Coherence properties of the infrared thermal radiation from individual heated nanowires are investigated as function of nanowire dimensions. Interfering the thermally induced radiation from a heated nanowire with its image in a nearby moveable mirror, well-defined fringes are observed. From the fringe visibility, the coherence length of the thermal emission radiation from the narrowest nanowires was estimated to be at least 20 um which is much larger than expected from a classical blackbody radiator. A significant increase in coherence and emission efficiency is observed for smaller nanowires.Comment: 4 pages,figures include

Learning and Recognizing Archeological Features from LiDAR Data

We present a remote sensing pipeline that processes LiDAR (Light Detection And Ranging) data through machine & deep learning for the application of archeological feature detection on big geo-spatial data platforms such as e.g. IBM PAIRS Geoscope. Today, archeologists get overwhelmed by the task of visually surveying huge amounts of (raw) LiDAR data in order to identify areas of interest for inspection on the ground. We showcase a software system pipeline that results in significant savings in terms of expert productivity while missing only a small fraction of the artifacts. Our work employs artificial neural networks in conjunction with an efficient spatial segmentation procedure based on domain knowledge. Data processing is constraint by a limited amount of training labels and noisy LiDAR signals due to vegetation cover and decay of ancient structures. We aim at identifying geo-spatial areas with archeological artifacts in a supervised fashion allowing the domain expert to flexibly tune parameters based on her needs

Locus for severity implicates CNS resilience in progression of multiple sclerosis

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that results in significant neurodegeneration in the majority of those affected and is a common cause of chronic neurological disability in young adults(1,2). Here, to provide insight into the potential mechanisms involved in progression, we conducted a genome-wide association study of the age-related MS severity score in 12,584 cases and replicated our findings in a further 9,805 cases. We identified a significant association with rs10191329 in the DYSF-ZNF638 locus, the risk allele of which is associated with a shortening in the median time to requiring a walking aid of a median of 3.7 years in homozygous carriers and with increased brainstem and cortical pathology in brain tissue. We also identified suggestive association with rs149097173 in the DNM3-PIGC locus and significant heritability enrichment in CNS tissues. Mendelian randomization analyses suggested a potential protective role for higher educational attainment. In contrast to immune-driven susceptibility(3), these findings suggest a key role for CNS resilience and potentially neurocognitive reserve in determining outcome in MS

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Online Updating of Computer Model Output Using Real-Time Sensor Data

<p>Data center thermal management has become increasingly important because of massive computational demand in information technology. To advance the understanding of the thermal environment in a data center, complex computer models are extensively used to simulate temperature distribution maps. However, due to management policies and time constraints, it is not practical to execute such models in a real time fashion. In this article, we propose a novel statistical modeling method to perform real-time simulation by dynamically fusing a <i>base</i>, steady-state solution of a computer model, and <i>real-time</i> thermal sensor data. The proposed method uses a Kalman filter and stochastic gradient descent method as computational tools to achieve real-time updating of the base temperature map. We evaluate the performance of the proposed method through a simulation study and demonstrate its merits in a data center thermal management application. Supplementary materials for this article are available online.</p